Anti-CCR9 Antibody

About SunRock Biopharma

SunRock Biopharma is a private, preclinical-stage biotech focused on developing novel antibodies for oncology, with a core expertise in targeting chemokine receptor CCR9 and the HER3 (ERBB3) pathway. The company has established a pipeline of mono- and bi-specific antibodies, with several HER3-targeting assets already licensed to Debiopharm, providing non-dilutive funding and validation. SunRock's strategy centers on addressing tumor metastasis and therapy resistance, positioning it in the competitive but high-value oncology biologics space.

Therapeutic Areas